Emerging molecular classifications and therapeutic implications for gastric cancer.

PubWeight™: 1.00‹?› | Rank: Top 15%

🔗 View Article (PMID 27233623)

Published in Chin J Cancer on May 27, 2016

Authors

Tao Chen1,2, Xiao-Yue Xu1,2, Ping-Hong Zhou3,4

Author Affiliations

1: Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Rd, Shanghai, 200032, P. R. China.
2: Endoscopy Research Institute, Fudan University, Shanghai, 200032, P. R. China.
3: Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Rd, Shanghai, 200032, P. R. China. pinghongzhou@yahoo.com.
4: Endoscopy Research Institute, Fudan University, Shanghai, 200032, P. R. China. pinghongzhou@yahoo.com.

Associated clinical trials:

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | NCT01848834

A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | NCT01094288

MLN8237 in Head and Neck Cancer | NCT01540682

Articles cited by this

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (2010) 25.32

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (2013) 7.77

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39

Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol (2004) 7.22

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42

Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer (2006) 4.99

Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84

Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer (2007) 4.16

Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell (2008) 4.01

Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev (2008) 3.67

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.53

The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer (2003) 3.21

Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87

Polo-like kinases and oncogenesis. Oncogene (2005) 2.86

The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer (2005) 2.83

Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology (2009) 2.39

The incidences and mortalities of major cancers in China, 2010. Chin J Cancer (2014) 2.39

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 2.35

Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27

Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol (1990) 2.13

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol (2014) 1.98

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med (2015) 1.93

Treatment of gastric cancer. World J Gastroenterol (2014) 1.93

Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res (2004) 1.83

Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A (2015) 1.72

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51

Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol (2004) 1.46

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38

Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer (2014) 1.32

Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol (2008) 1.26

Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res (1996) 1.17

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.17

Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep (2004) 1.14

Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology (2015) 1.13

Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res (2012) 1.10

17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer (1997) 1.06

Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep (2007) 1.05

Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer. Genes Chromosomes Cancer (2001) 1.05

Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol (2011) 1.02

Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol (2010) 1.00

Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol (2012) 1.00

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol (2015) 1.00

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer (2014) 1.00

TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer (2014) 0.99

Comparative analysis of protein expressions in primary and metastatic gastric carcinomas. Hum Pathol (2008) 0.97

Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene (2014) 0.97

Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol (2014) 0.96

Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol (2013) 0.95

Aurora kinase A in gastrointestinal cancers: time to target. Mol Cancer (2015) 0.90

A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer (2012) 0.89

Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) (2013) 0.87

Molecular classification and prediction in gastric cancer. Comput Struct Biotechnol J (2015) 0.85

Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med (2013) 0.84

Microsatellite instability in gastrointestinal tract cancers: a brief update. Surg Today (2005) 0.83

Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol (2015) 0.82

Targeting cell cycle kinases and kinesins in anticancer drug development. Expert Opin Drug Discov (2007) 0.80

From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract (2015) 0.80